Buy nexmed stocks

Our premium service offers you real-time quotes, advanced visualizations, technical studies, and much more. Become Elite and make informed financial decisions.

Your browser is no longer supported. Please, upgrade your browser. Healthcare Drug Manufacturers - Other USA. Edited Transcript of APRI earnings conference call or presentation May 8: Apricus posts 1Q profit Associated Press.

Apricus Biosciences Provides Corporate Update and First Quarter Financial Results GlobeNewswire. Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study GlobeNewswire. Apricus Biosciences Announces Corporate Update and First Quarter Financial Results Conference Call GlobeNewswire.

Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements GlobeNewswire ETFs with exposure to Apricus Biosciences, Inc.

April 19, Capital Cube. Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials Accesswire April 7, Capital Cube March 27, Capital Cube. Q4, By the Numbers: March 20, Capital Cube.

Pharma/Biotech Companies | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales

Apricus Biosciences Inc Earnings Call scheduled for 4: Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year Financial Results GlobeNewswire.

Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and. Q4 Apricus Biosciences Inc Earnings Release - 4: Apricus Biosciences Sells ED Therapy Rights Investopedia. Apricus Biosciences Sells ED Therapy Rights at Investopedia.

Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year Financial Results Conference Call GlobeNewswire. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D. Apricus Biosciences Announces Sale of Ex-U. Vitaros Assets and Rights to Ferring Pharmaceuticals GlobeNewswire. Files SEC form 8-K, Other Events.

Apricus Biosciences Receives Positive Nasdaq Listing Determination GlobeNewswire. Apricus APRI Stock Gains on Vitaros' Approval in Mexico.

Wednesdays Top Biopharma Winners. Latest Reports on Biocept and Apricus Biosciences as President Trump's Comments Put Pressure on Drug Manufacturers Accesswire.

NEXMED INC ( NEXM ) Stock Price Quote

Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel GlobeNewswire. Apricus Launches Vitaros in Lebanon for Erectile Dysfunction. December 13, Apricus Biosciences Receives Nasdaq Compliance Notice GlobeNewswire Apricus Biosciences Receives Nasdaq Compliance Notice GlobeNewswire.

Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Forex trading system com Listing Rule or S. Apricus International association forex traders to Present at the 9th Annual LD Buy nexmed stocks Main Event GlobeNewswire.

Complete Listing of All Wilshire Index Stocks

Files SEC form 8-K, Change in Directors or Principal Officers. Apricus Biosciences Aims to Resubmit Vitaros NDA in Files SEC form 8-K, Other Events Apricus Biosciences Provides Update on Vitaros NDA Following Receipt of FDA Feedback GlobeNewswire.

Q3, By the Numbers: Edited Transcript of APRI earnings conference call or presentation buy nexmed stocks 9: Apricus reports 3Q loss. Apricus Biosciences Provides Corporate Update and Third Quarter Financial Results GlobeNewswire.

Q3 Apricus Biosciences Inc Earnings Release - 4: Apricus Biosciences Announces Corporate Update and Can you earn money while on jobseekers allowance Quarter Financial Results Conference Call GlobeNewswire Apricus Biosciences Announces Corporate Update and Third Quarter Financial Results Conference Call GlobeNewswire.

Stock Quote APRI Apricus Biosciences, Inc.

Drug Makers Stocks Under Scanner -- Pernix Therapeutics, Novo Nordisk, Synergy Pharma, and Apricus Biosciences PR Newswire Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Arti. Here Are Two Biotechs That Are Down But Could Recover Near Term at Insider Monkey.

Apricus Biosciences splits before market open today 1: Apricus Biosciences Announces 1-for Reverse Stock Split GlobeNewswire. Apricus Biosciences to Present at the BIO Investor Forum GlobeNewswire Apricus Biosciences to Present at the BIO Investor Forum GlobeNewswire.

Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity. September 16, Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal, Ireland and Poland by Recordati GlobeNewswire. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction.

The company also engages in developing RayVa, which is in Phase 2 development for the treatment of Raynaud's Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. It operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc.